<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/729"/><api:result><api:object category="publication" id="729" last-affected-when="2024-04-02T06:00:10.933+01:00" last-modified-when="2024-03-14T05:56:23.91+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/729" created-when="2010-05-17T13:46:28.003+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-12-10</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="2224664" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1054/bjoc.1999.0880" last-modified-when="2023-06-03T00:47:09.95+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.1999.0880</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.1999.0880"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.1999.0880"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Science and Business Media LLC</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1054/bjoc.1999.0880</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>23</api:day><api:month>5</api:month><api:year>2023</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin’s disease and non-Hodgkin's lymphoma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="95793" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033988269" last-modified-when="2020-09-03T00:49:04.577+01:00"><api:citation-count>9</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12,800-£17,600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Faculty of Medicine, Dentistry and Health</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7006277551</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6604053967</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Faculty of Medicine, Dentistry and Health</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6701838000</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.1999.0880</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.1999.0880"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.1999.0880"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10638970</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="729" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10638970" last-modified-when="2020-04-28T21:31:30.263+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of 12 800 pound silver-17 600 pound silver, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">ScHARR, University of Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10638970</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.1999.0880</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.1999.0880"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.1999.0880"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pmc">PMC2363192</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Br J Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Disease-Free Survival</api:keyword><api:keyword scheme="mesh">Economics, Pharmaceutical</api:keyword><api:keyword scheme="mesh">Hodgkin Disease</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Recurrence</api:keyword><api:keyword scheme="mesh">Salvage Therapy</api:keyword><api:keyword scheme="mesh">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh">Time Factors</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0007092099908807</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>31</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Meta-Analysis</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="882018" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10638970" last-modified-when="2024-02-13T19:37:10.943+00:00"><api:citation-count>6</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of 12 800 pound silver-17 600 pound silver, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">ScHARR, University of Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-8875-2164</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.1999.0880</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.1999.0880"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.1999.0880"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10638970</api:identifier><api:identifier scheme="pmc">PMC2363192</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>true</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British journal of cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hodgkin Disease</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Recurrence</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Disease-Free Survival</api:keyword><api:keyword scheme="mesh">Salvage Therapy</api:keyword><api:keyword scheme="mesh">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh">Time Factors</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Economics, Pharmaceutical</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Open Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher-licence" type="text" display-name="Publisher licence"><api:text>CC BY</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>19</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Meta-Analysis</api:item><api:item>letter</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field><api:files><api:file proprietary-id="https://www.nature.com/articles/6690880.pdf"><api:file-url>https://www.nature.com/articles/6690880.pdf</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file><api:file proprietary-id="https://europepmc.org/articles/PMC2363192?pdf=render"><api:file-url>https://europepmc.org/articles/PMC2363192?pdf=render</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file></api:files></api:native></api:record><api:record format="native" id="2737023" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1013097444" last-modified-when="2023-11-25T21:42:58.593+00:00"><api:citation-count>6</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01237500524.53</api:identifier></api:identifiers></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Weston Park Cancer Centre</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01223762727.50</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0657257577.29</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.1999.0880</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.1999.0880"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.1999.0880"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10638970</api:identifier><api:identifier scheme="pmc">PMC2363192</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3201 Cardiovascular Medicine and Haematology</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Hematology</api:keyword><api:keyword scheme="rcdc">Hodgkin's Disease</api:keyword><api:keyword scheme="rcdc">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="rcdc">Comparative Effectiveness Research</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Lymphoma</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="sdg">3 Good Health and Well Being</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Disease-Free Survival</api:keyword><api:keyword scheme="mesh">Economics, Pharmaceutical</api:keyword><api:keyword scheme="mesh">Hodgkin Disease</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh">Recurrence</api:keyword><api:keyword scheme="mesh">Salvage Therapy</api:keyword><api:keyword scheme="mesh">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh">Time Factors</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>10</api:day><api:month>12</api:month><api:year>1999</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Hybrid OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Nature</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.13</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin’s disease and non-Hodgkin's lymphoma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="240998" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000084335900015" last-modified-when="2024-03-14T05:56:23.943+00:00"><api:citation-count>6</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000084335900015&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">267CA</api:identifier><api:identifier scheme="pubmed">10638970</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRITISH JOURNAL OF CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>Hodgkin's disease</api:keyword><api:keyword>lymphoma</api:keyword><api:keyword>cost-effectiveness</api:keyword><api:keyword>high dose chemotherapy</api:keyword><api:keyword>transplantation</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record><api:record format="native" id="23840" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000084335900015" last-modified-when="2014-07-25T11:05:16.86+01:00"><api:citation-count>5</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Beard</api:last-name><api:initials>SM</api:initials><api:first-names>SM</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Lorigan</api:last-name><api:initials>PC</api:initials><api:first-names>PC</api:first-names><api:separate-first-names><api:first-name>P</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="1437" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1437"/></api:links><api:last-name>Sampson</api:last-name><api:initials>FC</api:initials><api:first-names>FC</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>C</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRIT J CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>Hodgkin's disease</api:keyword><api:keyword>lymphoma</api:keyword><api:keyword>cost-effectiveness</api:keyword><api:keyword>high dose chemotherapy</api:keyword><api:keyword>transplantation</api:keyword><api:keyword>BONE-MARROW TRANSPLANTATION</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>81</api:begin-page><api:end-page>84</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>82</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Disease-Free Survival</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Economics, Pharmaceutical</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hodgkin Disease</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Recurrence</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Salvage Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Time Factors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hodgkin Disease</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Recurrence</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Disease-Free Survival</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Salvage Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Time Factors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Economics, Pharmaceutical</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3201 Cardiovascular Medicine and Haematology</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hematology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Hodgkin's Disease</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Comparative Effectiveness Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Lymphoma</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="sdg" origin="record-data" source="dimensions">3 Good Health and Well Being</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Disease-Free Survival</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Economics, Pharmaceutical</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hodgkin Disease</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Lymphoma, Non-Hodgkin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Recurrence</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Salvage Therapy</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Sensitivity and Specificity</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Time Factors</api:keyword><api:keyword origin="record-data" source="wos-lite">Hodgkin's disease</api:keyword><api:keyword origin="record-data" source="wos-lite">lymphoma</api:keyword><api:keyword origin="record-data" source="wos-lite">cost-effectiveness</api:keyword><api:keyword origin="record-data" source="wos-lite">high dose chemotherapy</api:keyword><api:keyword origin="record-data" source="wos-lite">transplantation</api:keyword><api:keyword origin="record-data" source="wos">Hodgkin's disease</api:keyword><api:keyword origin="record-data" source="wos">lymphoma</api:keyword><api:keyword origin="record-data" source="wos">cost-effectiveness</api:keyword><api:keyword origin="record-data" source="wos">high dose chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">transplantation</api:keyword><api:keyword origin="record-data" source="wos">BONE-MARROW TRANSPLANTATION</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0007-0920" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662" title="British Journal of Cancer"><api:records><api:record source-name="summary"><api:title>British Journal of Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/729/relationships"/></api:object></api:result></api:response>